234 related articles for article (PubMed ID: 33333786)
21. Degradation of p53 by HPV16-E6 variants isolated from cervical cancer specimens of Moroccan women.
Hadami K; Saby C; Dakka N; Collin G; Attaleb M; Khyatti M; Filali-Maltouf A; Morjani H; El Mzibri M
Gene; 2021 Jul; 791():145709. PubMed ID: 33984442
[TBL] [Abstract][Full Text] [Related]
22. The human papillomavirus E6 oncogene represses a cell adhesion pathway and disrupts focal adhesion through degradation of TAp63β upon transformation.
Ben Khalifa Y; Teissier S; Tan MK; Phan QT; Daynac M; Wong WQ; Thierry F
PLoS Pathog; 2011 Sep; 7(9):e1002256. PubMed ID: 21980285
[TBL] [Abstract][Full Text] [Related]
23. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene.
Spitkovsky D; Aengeneyndt F; Braspenning J; von Knebel Doeberitz M
Oncogene; 1996 Sep; 13(5):1027-35. PubMed ID: 8806692
[TBL] [Abstract][Full Text] [Related]
24. Perturbation of DROSHA and DICER expression by human papillomavirus 16 oncoproteins.
Harden ME; Munger K
Virology; 2017 Jul; 507():192-198. PubMed ID: 28448850
[TBL] [Abstract][Full Text] [Related]
25. HPV16 infection regulates RASSF1A transcription mediated by p53.
Lei Y; Hu C; Xu H; Tian Y
Mol Med Rep; 2013 Aug; 8(2):413-8. PubMed ID: 23779024
[TBL] [Abstract][Full Text] [Related]
26. A novel MLL5 isoform that is essential to activate E6 and E7 transcription in HPV16/18-associated cervical cancers.
Yew CW; Lee P; Chan WK; Lim VK; Tay SK; Tan TM; Deng LW
Cancer Res; 2011 Nov; 71(21):6696-707. PubMed ID: 21908553
[TBL] [Abstract][Full Text] [Related]
27. Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6.
Wang H; Mo P; Ren S; Yan C
J Biol Chem; 2010 Apr; 285(17):13201-10. PubMed ID: 20167600
[TBL] [Abstract][Full Text] [Related]
28. Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway.
Xu J; Xu S; Fang Y; Chen T; Xie X; Lu W
IUBMB Life; 2019 Mar; 71(3):347-356. PubMed ID: 30536701
[TBL] [Abstract][Full Text] [Related]
29. CRISPR/Cas9-based inactivation of human papillomavirus oncogenes E6 or E7 induces senescence in cervical cancer cells.
Inturi R; Jemth P
Virology; 2021 Oct; 562():92-102. PubMed ID: 34280810
[TBL] [Abstract][Full Text] [Related]
30. Silencing of human papillomavirus (HPV) E6/E7 oncogene expression affects both the contents and the amounts of extracellular microvesicles released from HPV-positive cancer cells.
Honegger A; Leitz J; Bulkescher J; Hoppe-Seyler K; Hoppe-Seyler F
Int J Cancer; 2013 Oct; 133(7):1631-42. PubMed ID: 23526637
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes.
Zhou J; Li B; Peng C; Wang F; Fu Z; Zhou C; Hong D; Ye F; Lü W; Xie X
Antiviral Res; 2013 May; 98(2):305-13. PubMed ID: 23523766
[TBL] [Abstract][Full Text] [Related]
32. E6 Protein Expressed by High-Risk HPV Activates Super-Enhancers of the
Chen X; Loo JX; Shi X; Xiong W; Guo Y; Ke H; Yang M; Jiang Y; Xia S; Zhao M; Zhong S; He C; Fu L; Li F
Cancer Res; 2018 Mar; 78(6):1418-1430. PubMed ID: 29339538
[TBL] [Abstract][Full Text] [Related]
33. Post-translational control of IL-1β via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53.
Niebler M; Qian X; Höfler D; Kogosov V; Kaewprag J; Kaufmann AM; Ly R; Böhmer G; Zawatzky R; Rösl F; Rincon-Orozco B
PLoS Pathog; 2013; 9(8):e1003536. PubMed ID: 23935506
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells.
Rincon-Orozco B; Halec G; Rosenberger S; Muschik D; Nindl I; Bachmann A; Ritter TM; Dondog B; Ly R; Bosch FX; Zawatzky R; Rösl F
Cancer Res; 2009 Nov; 69(22):8718-25. PubMed ID: 19887612
[TBL] [Abstract][Full Text] [Related]
35. Molecular analyses of unselected head and neck cancer cases demonstrates that human papillomavirus transcriptional activity is positively associated with survival and prognosis.
Masterson L; Winder DM; Ball SL; Vaughan K; Lehmann M; Scholtz LU; Sterling JC; Sudhoff HH; Goon PK
BMC Cancer; 2016 Jun; 16():367. PubMed ID: 27296171
[TBL] [Abstract][Full Text] [Related]
36. The PEI-introduced CS shell/PMMA core nanoparticle for silencing the expression of E6/E7 oncogenes in human cervical cells.
Saengkrit N; Sanitrum P; Woramongkolchai N; Saesoo S; Pimpha N; Chaleawlert-Umpon S; Tencomnao T; Puttipipatkhachorn S
Carbohydr Polym; 2012 Oct; 90(3):1323-9. PubMed ID: 22939347
[TBL] [Abstract][Full Text] [Related]
37. GSK3β mediates the carcinogenic effect of HPV16 in cervical cancer.
Ma C; Zeng C; Jin L; Yang Y; Li P; Chen L; Wang J
Sci Rep; 2015 Nov; 5():16555. PubMed ID: 26560046
[TBL] [Abstract][Full Text] [Related]
38. Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways.
Bischof O; Nacerddine K; Dejean A
Mol Cell Biol; 2005 Feb; 25(3):1013-24. PubMed ID: 15657429
[TBL] [Abstract][Full Text] [Related]
39. PDZ Domain-Containing Protein NHERF-2 Is a Novel Target of Human Papillomavirus 16 (HPV-16) and HPV-18.
Saidu NEB; Filić V; Thomas M; Sarabia-Vega V; Đukić A; Miljković F; Banks L; Tomaić V
J Virol; 2019 Dec; 94(1):. PubMed ID: 31597772
[TBL] [Abstract][Full Text] [Related]
40. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer.
Munagala R; Aqil F; Jeyabalan J; Gupta RC
Cancer Lett; 2015 Jan; 356(2 Pt B):536-46. PubMed ID: 25304375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
